Names, major classifications, and main uses of the 22 approved antimicrobials (2012–2022)
| Entry | Antibacterial drug | Approval year | Structural classification (categorization)a | Main use |
|---|---|---|---|---|
| 1 | Bedaquiline | 2012 | Diarylquinoline (“CI”) | Combination therapy with pulmonary multi-drug resistant tuberculosis (TB) |
| 2 | Dalbavancin | 2014 | Lipoglycopeptide (“CI”) | Acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms |
| 3 | Tedizolid | 2014 | Oxazolidinone (“CI”) | ABSSSI caused by designated susceptible bacteria |
| 4 | Ceftolozane-tazobactamb | 2014 | Cephalosporine and β-lactamase inhibitor (BLI; “CI”)b | Combination for: complicated intra-abdominal infections (cIAIs); complicated urinary tract infections (cUTIs); hospital-acquired bacterial pneumonia (HABP) |
| 5 | Oritavancin | 2015 | Lipoglycopeptide (“CI”) | ABSSSI by susceptible isolates of designated Gram-positive microorganisms |
| 6 | Ceftazidime-avicactamc | 2015 | Cephalosporine and BLI (“CI”)c | cIAI; cUTI; HABP |
| 7 | Obiltoxaximab | 2016 | Monoclonal antibody | Directed against the protective antigen of Bacillus anthracis |
| 8 | Bezlotoxumab | 2016 | Human monoclonal antibody | Reducing recurrence of Clostridium difficile infection (CDI) |
| 9 | Secnidazole | 2017 | Nitroimidazole (“I”) | Bacterial vaginosis in female patients; treatment of trichomoniasis |
| 10 | Delafloxacin | 2017 | Fluoroquinolone (“CI”) | ABSSSI, community-acquired bacterial pneumonia (CABP) |
| 11 | Meropenem-vaborbactamd | 2017 | Penem antibacterial and BLI (“CI”)d | cUTI |
| 12 | Ozenoxacin | 2017 | Quinolone (“CI”) | Topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes |
| 13 | Plazomicin | 2018 | Aminoglycoside (“CI”) | cUTI |
| 14 | Eravacycline | 2018 | Tetracycline (“HI”) | cIAI |
| 15 | Sarecycline | 2018 | Tetracycline | Inflammatory lesions of non-nodular moderate to severe acne vulgaris |
| 16 | Omadacycline | 2018 | Tetracycline (“HI”) | CABP, ABSSSI |
| 17 | Rifamycin | 2018 | Rifamycin (“CI”) | Travelers’ diarrhea caused by noninvasive strains of Escherichia coli |
| 18 | Imipenem-cilastatin-relebactame | 2019 | Penem antibacterial, renal dehydropeptidase inhibitor, and BLI (“CI”)e | cUTI; cIAI; HABP/ventilator-associated bacterial pneumonia (VABP) |
| 19 | Pretomanid | 2019 | First-in-class oxazine | Pulmonary extensively drug-resistant TB (XDR-TB) |
| 20 | Lefamulin | 2019 | First-in-class pleuromutilin antibacterial | CABP |
| 21 | Cefiderocol | 2019 | Cephalosporin | cUTI, including pyelonephritis and HABP/VABP |
| 22 | Vonoprazan | 2022 | A potassium-competitive acid blocker (PCAB) | Treatment of Helicobacter pylori infection |
a Categorization according to 2018 WHO’s inform; b both drugs are suministred in combination under the name Zerbaxa® and both are “CI”; c both drugs must be together administered under the name Avycaz® and both are “CI”; d both drugs are administered in combination under the name Vabomere® and both are “CI”; e sold under the brand name Recarbrio® is a fixed-dose combination medication